{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:38:19Z","timestamp":1794965899233,"version":"4.9.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ygyno.2025.11.020","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:59:36Z","timestamp":1765414776000},"page":"218-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review"],"prefix":"10.1016","volume":"204","author":[{"given":"Christina","family":"Washington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Miller-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.11.020_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0015","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0020","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0025","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"Mirza","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0035","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0040","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0045","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0050","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0055","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0070","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1136\/ijgc-2022-ESGO.488","article-title":"Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","volume":"32","author":"Coleman","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJMc1616633","article-title":"Niraparib in recurrent ovarian cancer","volume":"376","author":"Mirza","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonzalez-Martin","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0090","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0095","series-title":"OCR, SGO Clinical Practice Committee. SUMMARY: REVISIONS TO FDA APPROVALS FOR PARP INHIBITORS IN THE MANAGEMENT OF OVARIAN CANCER","author":"Urban","year":"2022"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0100","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5550","volume":"41","author":"Harter","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0110","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.ygyno.2024.07.096","volume":"190","author":"Harter","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0115","series-title":"Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA nonmutated epithelial ovarian cancer: Results from the randomized phase III ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study","author":"Powell","year":"2025"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0120","doi-asserted-by":"crossref","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0125","series-title":"GSK Announces FIRST Trial Met its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer","author":"GSK","year":"2024"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5506","article-title":"FIRST\/ENGOT-OV44: a phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in FIRST-line (1L) advanced ovarian cancer (aOC)","volume":"43","author":"Hardy-Bessard","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0135","series-title":"Zejula Updated Indication","author":"Rx","year":"2025"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0140","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ygyno.2023.06.508","article-title":"Final overall survival and long-term safety in the ENGOT-OV16\/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer","volume":"176","author":"Matulonis","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0150","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2217\/fon-2019-0271","article-title":"Olaparib in the treatment of ovarian cancer","volume":"15","author":"Washington","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0155","series-title":"Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer","author":"Ledermann","year":"2025"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102629","article-title":"Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial","volume":"72","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","volume":"167","author":"O\u2019Malley","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0170","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","article-title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial","volume":"34","author":"Pujade-Lauraine","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0175","series-title":"Dear Health Care Provider Letter (Niraparib)","author":"GlaxoSmithKline","year":"2022"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0185","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0190","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0195","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0200","series-title":"Dear Healthcare Professional Letter","author":"AstraZeneca","year":"2022"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0205","series-title":"Exchange Commission: Form 8-k","author":"Clovis Oncology I. UNITED STATES SECURITIES AND","year":"2022"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0210","series-title":"SUMMARY: Revisions to FDA Approvals for Parp Inhibitors in the Management of Ovarian CANCER Federal Regulations","author":"Urban R. OCR","year":"2022"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0215","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO-24-02834","article-title":"Overall survival and the evolving benefit-risk assessment for poly (ADP-ribose) polymerase inhibitors in advanced ovarian cancer","volume":"43","author":"Shah","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0220","doi-asserted-by":"crossref","first-page":"1162665","DOI":"10.3389\/fphar.2023.1162665","article-title":"Olaparib and advanced ovarian cancer: Summary of the past and looking into the future","volume":"14","author":"Maiorano","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0225","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0230","first-page":"14","article-title":"PARP inhibitors resistance: mechanisms and perspectives","author":"Giudice","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0235","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/2159-8290.CD-17-0734","article-title":"Reversion mutations with clinical use of PARP inhibitors: many genes, many versions","volume":"7","author":"Domchek","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","article-title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","volume":"32","author":"Tobalina","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5559","article-title":"BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer","volume":"40","author":"Lukashchuk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0255","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0260","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","article-title":"EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression","volume":"26","author":"Lheureux","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0265","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0270","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2022.11.027","article-title":"AML and MDS associated with PARP inhibitor treatment of ovarian cancer","volume":"171","author":"Armstrong","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0275","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00395-022-00969-w","article-title":"Clonal hematopoiesis and cardiovascular disease: deciphering interconnections","volume":"117","author":"Stein","year":"2022","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0285","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0290","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/s41375-024-02253-3","article-title":"Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer","volume":"38","author":"Arends","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104893","article-title":"Effectiveness and safety of PARP inhibitors in ovarian cancer: an umbrella review of systematic reviews and meta-analyses","volume":"215","author":"Tzang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0300","first-page":"Cd007929","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","volume":"2","author":"Tattersall","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0305","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.41648","article-title":"PARP inhibitor maintenance after first-line chemotherapy in advanced-stage epithelial ovarian cancer: a systematic review and meta-analysis","volume":"8","author":"Petousis","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0310","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0315","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2023.05.006","article-title":"Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: a joint statement from GOG Foundation and Society of Gynecologic Oncology (SGO)","volume":"174","author":"Pothuri","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0320","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46494","article-title":"Racial and ethnic disparities in clinical trial enrollment among women with gynecologic cancer","volume":"6","author":"Khadraoui","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0325","series-title":"Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","author":"Coleman","year":"2022"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0330","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ijgc-2022-004190","article-title":"Myeloid neoplasms post PARP inhibitors for ovarian cancer","volume":"33","author":"Caruso","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.11.020_bb0335","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.020_bb0340","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/2767-9764.CRC-22-0423","article-title":"The PARP1 inhibitor AZD5305 impairs ovarian adenocarcinoma progression and visceral metastases in patient-derived xenografts alone and in combination with carboplatin","volume":"3","author":"Dellavedova","year":"2023","journal-title":"Cancer Res. Commun."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825011151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825011151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:18:53Z","timestamp":1768396733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825011151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":68,"alternative-id":["S0090825825011151"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}